An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Phase
3Span
211 weeksSponsor
Karuna TherapeuticsVrsac
Recruiting
1-1 of 1